NHSE recommends Chiesi’s nephropathic cystinosis treatment for routine commissioning
NHS England has recommended Chiesi’s delayed-release mercaptamine bitartrate (a cystine-depleting agent) for routine commissioning for eligible patients living with nephropathic cystinosis. The decision means...
- Advertisement - 
- Advertisement -
- Advertisement -
What are the opportunities and challenges in the UK rare disease environment?
Following the the launch of England’s first Rare Diseases Action Plan, Craig Bradley explores...
PM Society Digital Awards Winners 2021
Winners from the 12th PM Society Digital Awards have been announced after the event...
Protecting Q2 revenue: Commercial capability life sciences leaders need now
Q2 is a decisive quarter for commercial performance, but the pressure of 2026 is sharpening. Targets tighten, promotional pace increases, and HCP access becomes...
From reach to resonance: redefining HCP engagement in the AI era
For years, commercial success in pharma was measured by reach – how many HCPs we engaged, how often, and across how many channels. Omnichannel...
Workforce continuity: Why permanent hiring matters
As HR Directors and TA leaders finalise headcount plans, one truth is cutting through the noise: the organisations that will hit their clinical and...
- Advertisement -
- Advertisement -
Cambridge scientists develop test to revolutionise prostate diagnosis
To revolutionise screening and diagnosis of prostate cancer, scientists in Cambridge have developed an advanced test designed to accelerate personalised treatment for patients.
The innovative...
Janssen seeks approval for its multiple myeloma treatment
Janssen has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).
Talquetamab is an investigational, off-the-shelf (ready to...
Symeres and Axxam appoint Russell Thomas as Chief Scientific Officer to lead integrated discovery platform
Symeres, a leading contract research, development and manufacturing organisation, and Axxam, a leading provider...
Oriva Therapeutics appoints new CEO to advance women’s health pipeline
Oriva Therapeutics, a women’s health company developing first-in-class approaches to treat chronic, prevalent conditions...
AbbVie Appoints Kelly Sanderson Schrems as UK Vice President and General Manager
AbbVie has announced that Kelly Sanderson Schrems has been appointed as Vice President and General Manager,...
VIDEO > LATEST
On demand: Maximising pharma’s commercial impact with brand optimisation
Uniphar’s Client Solutions Director, Mark Ward, and Director of Consulting, Nick Bartlett, chair a Pf Media and Uniphar webinar, ‘Maximising pharma’s commercial impact with...
